TherapeuticsMD (NYSE:TXMD) Receives New Coverage from Analysts at started coverage on shares of TherapeuticsMD (NYSE:TXMDGet Rating) in a research note issued to investors on Friday. The brokerage set a “sell” rating on the stock.

Shares of NYSE:TXMD opened at $2.98 on Friday. TherapeuticsMD has a one year low of $2.86 and a one year high of $69.50. The firm’s fifty day moving average is $0.55.

TherapeuticsMD (NYSE:TXMDGet Rating) last posted its quarterly earnings results on Thursday, March 10th. The company reported ($0.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.03). The firm had revenue of $18.68 million for the quarter, compared to analyst estimates of $30.07 million.

TherapeuticsMD Company Profile (Get Rating)

TherapeuticsMD, Inc operates as a women's healthcare company in the United States. The company offers IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of 17ß-estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms; and ANNOVERA, a ring-shaped contraceptive vaginal system.

See Also

Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with's FREE daily email newsletter.